The business continuity plan is a tool to help the European Medicines Agency (EMA) take the difficult decision to reallocate the available resources as needed to maintain its priority activities over the next years. It categorises and prioritises tasks and activities according to their impact on public health and the Agency’s ability to function.
Noel Wathion, EMA’s Deputy Executive Director and head of EMA’s Brexit task force, said: “Preparing for the move, managing the necessary changes and addressing challenges such as possible losses in skilled and experienced staff, in a proactive and efficient way requires considerable internal resources."
With the business continuity plan we aim to ensure the assessment of medicines is not disrupted and that patients in Europe continue to have access to high quality, safe and effective medicines.
Category 1
The highest priority activities either directly related to the assessment and safety monitoring of medicines or vital to maintaining the infrastructure of the European regulatory system for medicines, including the coordination of actions to protect the safety of patients in all EU Member States, inspections across the EU or maintenance of the functionality and security of critical IT applications used by all Member States.
Category 2
The second highest priority includes proactive publication of clinical data and various initiatives aimed at promoting availability of medicines as well as some political priorities of the EU, for example, EMA’s contribution to the fight against antimicrobial resistance. These activities will be maintained for as long as possible, workload and staffing situation permitting, in order to maintain the development of new medicines.
Category 3
In May, EMA started to scale back activities in the outer layer activities, to free up 43 staff by the end of 2017 who are focusing on the preparations for the UK’s withdrawal from the EU and EMA’s relocation. To achieve this, the Agency decided to temporarily suspend a number of activities including: the development of the European Medicines Web Portal; EMA’s contribution to the e-submission project allowing applicants to electronically submit documents; development of a transparency roadmap for EMA; participation in the benchmarking of medicines regulatory authorities in the EU as of 2018.
In addition, EMA reduced the number of audits as well as some corporate governance and support activities. Participation of EMA staff in external meetings or conferences has been reduced, as has the organisation of EMA meetings and workshops.
These types of activities can be put on hold for some time to free up or channel resources into core activities that must be maintained under any circumstances. However, mid-to-long-term EMA will need to analyse how long these activities can be put on hold before they start to seriously undermine the quality of the Agency’s work and its planning, and the expectations of stakeholders.
Further iterations of the business continuity plan will also take into account various scenarios for staff losses and how these may affect the delivery of category 1 and 2 activities. Unexpected higher, faster or more permanent loss of staff as a consequence of the Agency’s relocation may lead to a situation in which EMA’s operations can no longer be maintained.
